Health related quality of life results through week 22 from the CERTIFI study, a multicenter, randomized, double-blind, placebo-controlled phase2b study of Ustekinumab in patients with moderately to severely active Crohnʼs disease

2011 ◽  
Vol 17 ◽  
pp. S24 ◽  
Author(s):  
BE Sands ◽  
C Gasink ◽  
L-L Gao ◽  
MA Blank ◽  
J Johanns ◽  
...  
Sign in / Sign up

Export Citation Format

Share Document